Chemotherapy-Induced Reduction of Neutrophil-to-Lymphocyte Ratio Is Associated With Better Survival in Pancreatic Adenocarcinoma: A Meta-Analysis

Overview

Journal Cancer Control

Specialty Oncology

Date 2020 Dec 3

PMID 33269614

Citations 2

Authors

Xin Luo

Bo Yu

Nan Jiang

Qiong Du

Xuan Ye

Huan Li

Wen-Quan Wang

Qing Zhai

Affiliations

Soon will be listed here.

Abstract

Objectives: Numerous studies have suggested that an increase in neutrophil-to-lymphocyte ratio (NLR) before treatment is associated with worse survival in pancreatic adenocarcinoma (PAC). The aim of this study was to investigate the prognostic value of treatment-induced NLR change among PAC patients so as to better identify the characteristics of those who can benefit more from treatment.

Methods: This meta-analysis was undertaken using the PRISMA statement. Previously published studies between the correlation of NLR change and patients' survival were searched in Pubmed, Embase, and Web of Science databases. RevMan 5.3 was used to conduct statistical analysis.

Results: A total of 1213 patients with PAC from 6 retrospective studies were included in this meta-analysis. Four studies investigated the HR of pre-treatment NLR, demonstrating its prognostic impact on overall survival (OS) (HR = 2.21, 95%CI: 1.45-3.36). One study reported that an elevated post-treatment NLR was associated with poorer OS (HR = 1.28, 95%CI = 1.08-1.52). Pooled analysis indicated that NLR reduction might predict favorable survival in both the overall population (HR = 1.52, 95% CI: 1.34-1.73) and the subgroup treated with chemotherapy (HR = 1.50, 95% CI: 1.32-1.70).

Conclusion: Treatment-induced NLR change can act as an early predictor for PAC. Patients with reduced NLR after chemotherapy are expected to have better survival.

Citing Articles

The rest period between chemotherapy and immunotherapy influences the efficacy of immune checkpoint inhibitors in lung cancer.

Kang D, Choi S, Sun P, Chung C, Park D, Lee S Thorac Cancer. 2022; 13(16):2346-2354.

PMID: 35818294 PMC: 9376175. DOI: 10.1111/1759-7714.14568.

Neutrophil-to-lymphocyte ratio is associated with sensitivity to platinum-based chemotherapy and prognosis in patients with advanced serous ovarian carcinoma.

Fukuda T, Kawanishi M, Awazu Y, Nanno S, Shimomura M, Inoue Y Mol Clin Oncol. 2021; 15(4):217.

PMID: 34476101 PMC: 8408678. DOI: 10.3892/mco.2021.2381.

References

Jomrich G, Paireder M, Kristo I, Baierl A, Ilhan-Mutlu A, Preusser M . High Systemic Immune-Inflammation Index is an Adverse Prognostic Factor for Patients With Gastroesophageal Adenocarcinoma. Ann Surg. 2019; 273(3):532-541. DOI: 10.1097/SLA.0000000000003370. View

Chen Y, Wang Y, Deng G, Dai G . CA19-9 decrease and survival according to platelet level in patients with advanced pancreatic cancer. BMC Cancer. 2019; 19(1):860. PMC: 6716806. DOI: 10.1186/s12885-019-6078-2. View

Oh D, Pyo J, Son B . Prognostic Roles of Inflammatory Markers in Pancreatic Cancer: Comparison between the Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio. Gastroenterol Res Pract. 2018; 2018:9745601. PMC: 6011084. DOI: 10.1155/2018/9745601. View

Chen Y, Yan H, Wang Y, Shi Y, Dai G . Significance of baseline and change in neutrophil-to-lymphocyte ratio in predicting prognosis: a retrospective analysis in advanced pancreatic ductal adenocarcinoma. Sci Rep. 2017; 7(1):753. PMC: 5429710. DOI: 10.1038/s41598-017-00859-5. View

Miyamoto R, Oda T, Hashimoto S, Kurokawa T, Kohno K, Akashi Y . Platelet × CRP Multiplier Value as an Indicator of Poor Prognosis in Patients With Resectable Pancreatic Cancer. Pancreas. 2016; 46(1):35-41. DOI: 10.1097/MPA.0000000000000697. View

Liu X, Sun X, Liu J, Kong P, Chen S, Zhan Y . Preoperative C-Reactive Protein/Albumin Ratio Predicts Prognosis of Patients after Curative Resection for Gastric Cancer. Transl Oncol. 2015; 8(4):339-45. PMC: 4562973. DOI: 10.1016/j.tranon.2015.06.006. View

Bhatti I, Peacock O, Lloyd G, Larvin M, Hall R . Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg. 2010; 200(2):197-203. DOI: 10.1016/j.amjsurg.2009.08.041. View

Demirci N, Erdem G . Prognostic role of neutrophil-to-lymphocyte ratio (NLR) in patients with operable ampullary carcinoma. Bosn J Basic Med Sci. 2017; 18(3):268-274. PMC: 6087558. DOI: 10.17305/bjbms.2017.2530. View

Gu X, Tian T, Tian X, Zhang X . Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis. Sci Rep. 2015; 5:12493. PMC: 4513342. DOI: 10.1038/srep12493. View

10.

Ko A, Hwang J, Venook A, Abbruzzese J, Bergsland E, Tempero M . Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer. 2005; 93(2):195-9. PMC: 2361548. DOI: 10.1038/sj.bjc.6602687. View

11.

Tsujita E, Ikeda Y, Kinjo N, Yamashita Y, Hisano T, Furukawa M . Postoperative Neutrophil-to-Lymphocyte Ratio as a Predictor of Long-Term Prognosis after Pancreatectomy for Pancreatic Carcinoma: A Retrospective Analysis. Am Surg. 2017; 83(6):610-616. View

12.

Sharaiha R, Halazun K, Mirza F, Port J, Lee P, Neugut A . Elevated preoperative neutrophil:lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer. Ann Surg Oncol. 2011; 18(12):3362-9. PMC: 3192937. DOI: 10.1245/s10434-011-1754-8. View

13.

Chua W, Charles K, Baracos V, Clarke S . Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer. 2011; 104(8):1288-95. PMC: 3078587. DOI: 10.1038/bjc.2011.100. View

14.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

15.

Gao Y, Wang W, Zhi Q, Shen M, Jiang M, Bian X . Neutrophil/lymphocyte ratio is a more sensitive systemic inflammatory response biomarker than platelet/lymphocyte ratio in the prognosis evaluation of unresectable pancreatic cancer. Oncotarget. 2017; 8(51):88835-88844. PMC: 5687650. DOI: 10.18632/oncotarget.21340. View

16.

Ducreux M, Seufferlein T, Van Laethem J, Laurent-Puig P, Smolenschi C, Malka D . Systemic treatment of pancreatic cancer revisited. Semin Oncol. 2019; 46(1):28-38. DOI: 10.1053/j.seminoncol.2018.12.003. View

17.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

18.

Glazer E, Rashid O, Pimiento J, Hodul P, Malafa M . Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma. Surgery. 2016; 160(5):1288-1293. PMC: 5086285. DOI: 10.1016/j.surg.2016.04.039. View

19.

Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMC: 1920534. DOI: 10.1186/1745-6215-8-16. View

20.

Ichikawa K, Mizuno S, Hayasaki A, Kishiwada M, Fujii T, Iizawa Y . Prognostic Nutritional Index After Chemoradiotherapy Was the Strongest Prognostic Predictor Among Biological and Conditional Factors in Localized Pancreatic Ductal Adenocarcinoma Patients. Cancers (Basel). 2019; 11(4). PMC: 6520898. DOI: 10.3390/cancers11040514. View